DERL2

DERL2 (Derlin-2) is a core component of the mammalian ER-associated degradation (ERAD) retrotranslocation machinery, coupling recognition of misfolded ER lumenal substrates to their extraction into the cytosol for proteasomal destruction (PMID:16449189). It physically bridges the misfolded-glycoprotein receptor EDEM and the cytosolic extraction ATPase p97, and its own transcription is induced by the IRE1 branch of the unfolded protein response, integrating it into ER stress signaling (PMID:16449189). Within retrotranslocation, DERL2 acts upstream of Derlin-1 and Surf4: it engages substrate (COX-2) in an N-glycosylation-independent manner and is required for substrate ubiquitylation and handoff to the Derlin-1–Surf4–caveolin-1–p97 axis (PMID:37676109), and it likewise supports HRD1/p97-dependent degradation of proinsulin (PMID:26107514). In vivo, DERL2 is essential for protein dislocation in chondrocytes, where its loss disrupts collagen matrix secretion and causes skeletal dysplasia and perinatal lethality with constitutive UPR activation (PMID:21220515), and it maintains ER homeostasis in podocytes, preventing caspase-12-dependent apoptosis under ER stress (PMID:29167172). Beyond classical ERAD, DERL2 supports postnatal brain development by enabling SREBP-2-mediated cholesterol biosynthesis (PMID:34355142) and stabilizes the co-chaperone BAG6 by extending its half-life, a non-ERAD activity that reinforces tumor progression and chemoresistance in cholangiocarcinoma (PMID:37815698). DERL2 is also exploited by murine polyomavirus to translocate its genome from the ER lumen to the cytosol (PMID:16912321).

1. 2006 High

   Established DERL2 as the mechanistic link between lumenal substrate recognition and cytosolic extraction in ERAD, answering how misfolded glycoproteins are routed for retrotranslocation.

   Evidence Reciprocal co-IP of Derlin-2 with EDEM and p97, plus overexpression and siRNA degradation assays and UPR branch-specific induction analysis

   PMID:16449189

   Open questions at the time

   • Does not resolve whether DERL2 itself forms the conducting channel or only scaffolds the complex
   • Stoichiometry and structural arrangement of the EDEM–DERL2–p97 complex not defined
2. 2006 High

   Showed that DERL2-dependent retrotranslocation is hijacked by a pathogen, demonstrating the machinery can move non-host cargo (viral genome) from ER to cytosol.

   Evidence Dominant-negative overexpression and shRNA knockdown in polyomavirus infection assays with a cytosolic-DNA bypass experiment

   PMID:16912321

   Open questions at the time

   • How the viral particle/genome is physically accommodated by the ERAD channel is unknown
   • Direct interaction between DERL2 and viral components not established
3. 2011 High

   Defined the in vivo physiological requirement for DERL2, showing it is essential for chondrocyte secretory homeostasis but dispensable in some secretory tissues, revealing tissue-specific dependence on this ERAD route.

   Evidence Conditional Cre-lox knockout mice with histology, ER chaperone/UPR marker analysis, and tissue-specific deletions

   PMID:21220515

   Open questions at the time

   • Molecular basis for tissue-selective requirement (chondrocyte vs B cell/hepatocyte) not explained
   • Specific endogenous chondrocyte substrate(s) not identified
4. 2015 Medium

   Extended DERL2 substrate scope to proinsulin, placing it in an HRD1/p97-dependent degradation route in beta cells.

   Evidence shRNA knockdown with steady-state proinsulin Western blot and MHC class I ligandome analysis

   PMID:26107514

   Open questions at the time

   • Single primary method (knockdown) without reconstitution
   • Direct DERL2–proinsulin interaction not demonstrated
5. 2017 Medium

   Linked DERL2 ERAD function to cell survival, showing its loss removes a compensatory ER stress buffer and triggers caspase-12-dependent apoptosis in podocytes.

   Evidence Podocyte-specific knockout and overexpression rescue in an adriamycin injury model with caspase-12 pathway analysis

   PMID:29167172

   Open questions at the time

   • Direct DERL2 substrates in podocytes not identified
   • Mechanistic connection between DERL2 loss and caspase-12 activation not fully defined
6. 2021 Medium

   Revealed a non-classical DERL2 role in development by connecting it to SREBP-2-driven cholesterol biosynthesis required for postnatal brain maturation.

   Evidence CNS-specific conditional knockout mice, neurite outgrowth assays, SREBP-2 pathway rescue, and behavioral motor testing

   PMID:34355142

   Open questions at the time

   • How DERL2 mechanistically engages the SREBP-2 pathway is not resolved
   • Whether the effect is through canonical ERAD of an SREBP regulator is unclear
7. 2023 Medium

   Ordered the retrotranslocation complex, placing DERL2 upstream of Derlin-1 and Surf4 and defining glycosylation-state-dependent substrate handoff for COX-2.

   Evidence CRISPR library screening, siRNA knockdown, co-IP, ubiquitylation assays, and N-glycosylation mutant analysis

   PMID:37676109

   Open questions at the time

   • Structural basis of the sequential DERL2→DERL1→Surf4 handoff unknown
   • Generality of this ordered axis across other substrates untested
8. 2023 Medium

   Identified a non-ERAD DERL2 activity as a stabilizer of the co-chaperone BAG6, linking DERL2 to oncogenic protein homeostasis and chemoresistance.

   Evidence Co-IP of DERL2–BAG6, protein half-life assay, knockout/overexpression, and gemcitabine sensitivity and tumor growth assays in cholangiocarcinoma

   PMID:37815698

   Open questions at the time

   • Mechanism by which DERL2 extends BAG6 half-life is undefined
   • Whether this requires ERAD machinery or is independent of it is unresolved

• Whether DERL2 itself forms a substrate-conducting channel or acts purely as a scaffold, and the structural architecture of its sequential retrotranslocation complex, remains open.
• No structural model of DERL2 within the retrotranslocon
• Pore-forming vs adaptor function unresolved
• Comprehensive endogenous substrate repertoire not mapped